8 minutes read

PET-MR (PET combined with MRI in a single integrated scanner) is a newer, more complex imaging modality for specific clinical applications, not a general “upgrade” to PET-CT. China’s PET-MR installations have accelerated meaningfully in recent years — from 23 units in 2020 to 51 in 2024, with the “14th Five-Year Plan” targeting 210 total [1][2]. But PET-MR is not “PET-CT plus better” — it’s meaningfully superior to PET-CT in neurological, pediatric, hepatobiliary, prostate cancer, head & neck, gynecological, cardiac, and hematological applications, while PET-CT remains the standard for most whole-body cancer staging. This article walks through China’s PET-MR availability, the clinical scenarios where PET-MR is preferred, pricing, and how to decide whether you need PET-MR or PET-CT.

What Is PET-MR and Why It Matters

PET-MR combines PET (functional/metabolic imaging) + MRI (high-contrast soft tissue imaging) in a single integrated scanner — both datasets acquired in one examination, with MR’s soft tissue contrast far exceeding CT’s.

Fundamental differences from PET-CT:

Dimension PET-CT PET-MR
Anatomical imaging CT (excellent for bone, lung, air contrast) MRI (excellent for soft tissue)
Radiation dose ~10–20 mSv ~3–5 mSv (reduced by ~70%)
Scan duration 20–30 minutes 45–90 minutes (longer)
Soft tissue contrast Moderate Very high
Whole-body screening Excellent Slightly weaker (smaller field of view)
Neurological, hepatobiliary, prostate, and other specific scenarios Good Excellent

PET-MR Availability in China (as of 2026)

Total nationwide installations: According to the 2024 Chinese Medical Association Nuclear Medicine Branch survey, mainland China had 51 PET-MR units installed — doubled from 23 just four years earlier [1]. The “14th Five-Year Plan” sets the total at 210 units with 141 new installations [2] — meaning 2026 actual installations should be in the 80–120 range.

Key regulatory change: In March 2023, the National Health Commission downgraded PET-MR from Class A to Class B large medical equipment [3] — shifting approval from “National Health Commission approval” to “Provincial Health Commission approval,” significantly lowering the configuration threshold. This is the core policy driver behind the post-2023 acceleration in Chinese PET-MR installations.

Provincial allocations: Shanghai plans 21 units, Beijing 16, Guangdong 16 [2] — these three provinces are where international patients are most likely to find PET-MR.

Major PET-MR Centers in China

The list below covers known installations; PET-MR availability changes frequently, and not every hospital that recently installed has published the information publicly. The most accurate way to confirm current availability is through the hospital IMD or a coordination service.

Beijing:

  • PLA General Hospital (301) — early-installation site
  • Xuanwu Hospital (GE SIGNA PET/MR) — domestic leader in neurological PET-MR; participated in the CAMIND multi-tracer PET-MR clinical trial [4]
  • Peking Union Medical College Hospital — through the IMS International Medical Department
  • China-Japan Friendship Hospital — comprehensive nuclear medicine capability

Shanghai:

  • Fudan University Zhongshan Hospital — the city’s most comprehensive nuclear medicine system (also the global first installation site of the uEXPLORER total-body PET-CT)
  • Fudan University Shanghai Cancer Center — oncology-focused PET-MR
  • Shanghai Renji Hospital (Shanghai Jiao Tong University) — comprehensive imaging
  • Shanghai Quanjing Medical Imaging Diagnostic Center — third-party premium imaging
  • Shanghai US-China Joint Medical Imaging Center — third-party premium imaging

Guangzhou:

  • Sun Yat-sen University Cancer Center (SYSUCC) — oncology-leading; PSMA PET-MR and other tracers commonly available
  • Sun Yat-sen University 1st Affiliated Hospital — major Greater Bay Area international patient entry point

Shenzhen:

  • The University of Hong Kong-Shenzhen Hospital (HKU-SZH) — Hong Kong-style service + standardized bilingual reporting

Hangzhou:

  • Zhejiang University 2nd Affiliated Hospital International Medical Center (GE SIGNA PET/MR) — one of the most international patient-friendly PET-MR centers in the Yangtze River Delta

Chengdu:

  • West China Hospital — the only confirmed PET-MR installation at a top-tier Tier-3A in southwest China

Changsha:

  • Xiangya Hospital — Central China representative

Ningbo:

  • Mingzhou Hospital

Main equipment models:

  • Siemens Biograph mMR
  • GE SIGNA PET/MR
  • United Imaging uPMR 790 / uMR Jupiter PET/MR (China-domestic) — leading market share in new installations after 2020

Eight Scenarios Where PET-MR Outperforms PET-CT

Scenario 1 · Neurological disease

PET-MR has clear advantages in brain tumors, Alzheimer’s disease, and epilepsy localization — MR’s brain tissue contrast far exceeds CT, and combined with PET showing metabolic or receptor distribution, it’s the gold standard for this category.

Xuanwu Hospital’s CAMIND multi-tracer PET-MR clinical trial (NCT06092125, 2022–2028) targets exactly this area [4].

Applications:

  • Brain glioma grading and biopsy targeting
  • Early Alzheimer’s diagnosis (β-amyloid / Tau PET-MR)
  • Difficult-to-treat epilepsy precision foci localization
  • Detailed assessment of brain metastases

Scenario 2 · Pediatric oncology

PET-MR’s radiation dose of ~3–5 mSv represents a ~70% reduction compared with PET-CT [5]. For pediatric patients and adolescents requiring repeated surveillance, this radiation reduction has standalone medical value — lower long-term cumulative dose, lower long-term cancer risk.

Applications:

  • Pediatric lymphoma staging and surveillance
  • Pediatric bone and soft tissue tumors
  • Neuroblastoma staging

Scenario 3 · Hepatobiliary and pancreatic cancers

PET-MR combines multi-parametric MR (DWI + hepatobiliary-specific contrast Gd-EOB-DTPA) + FDG / FAPI PET, with sensitivity for liver metastases, primary liver cancer, and pancreatic cancer significantly higher than PET-CT [6].

Applications:

  • Hepatocellular carcinoma staging
  • Detection of colorectal cancer liver metastases
  • Pancreatic cancer (especially combined with FAPI tracer)
  • Cholangiocarcinoma

Scenario 4 · Prostate cancer (PSMA PET-MR)

68Ga-PSMA PET-MR outperforms PET-CT for prostate local staging and neurovascular bundle involvement assessment [7] — MR’s pelvic soft tissue resolution is the key.

Applications:

  • Precision local staging of prostate cancer
  • Neurovascular bundle involvement assessment (determines feasibility of nerve-sparing surgery)
  • Local recurrence assessment after biochemical recurrence

Scenario 5 · Head and neck cancer

For local-regional staging of oropharyngeal squamous cell carcinoma and other head and neck cancers, PET-MR outperforms PET-CT [8] — the head and neck’s complex soft tissue structures benefit from MR’s high contrast.

Applications:

  • Oropharyngeal squamous cell carcinoma
  • Nasopharyngeal carcinoma (especially skull base involvement assessment, combining well with SYSUCC’s nasopharyngeal cancer expertise)
  • Laryngeal cancer
  • Cervical lymph node assessment

Scenario 6 · Gynecological cancers

For cervical cancer, endometrial cancer, and ovarian cancer, PET-MR offers superior pelvic soft tissue contrast and is particularly valuable for:

  • Local extension assessment (parametrial invasion, vaginal involvement, bladder/rectal invasion)
  • Pelvic and para-aortic lymph node staging
  • Treatment response evaluation
  • Recurrence localization after primary treatment

PET-MR is increasingly preferred over PET-CT in many gynecologic oncology centers internationally for staging decisions that affect surgical approach.

Scenario 7 · Cardiac PET-MR

Cardiac PET-MR combines metabolic information (PET) with the cine sequences and tissue characterization (LGE, T1/T2 mapping) of cardiac MR. Particularly valuable for:

  • Cardiac sarcoidosis — distinguishing active inflammation from fibrosis
  • Myocarditis — assessing inflammation and necrosis
  • Cardiac viability assessment — pre-revascularization planning
  • Cardiac tumors — characterization and staging

Cardiac PET-MR is a specialized application; not all PET-MR centers have the cardiac expertise to interpret it well.

Scenario 8 · Multiple myeloma and bone marrow disease

PET-MR’s combination of whole-body MRI (with diffusion-weighted imaging) + FDG PET provides comprehensive bone marrow assessment that PET-CT alone cannot match. Particularly valuable for:

  • Multiple myeloma staging (replacing or complementing skeletal survey)
  • Treatment response assessment in multiple myeloma
  • Diffuse marrow involvement evaluation
  • Solitary plasmacytoma versus multiple myeloma differentiation

For multiple myeloma patients, PET-MR is increasingly considered a preferred imaging modality in international guidelines.

Pricing

PET-MR pricing is higher than PET-CT, but the gap has meaningfully narrowed in recent years:

Type Price Range (USD) Notes
Public Tier-3A full-body PET-MR (in price-adjusted provinces: Shanghai, Guangdong, etc.) $1,290–$1,330 (regulatory ceiling) Within the ceiling, hospitals set their own pricing
Public Tier-3A full-body PET-MR (in not-yet-adjusted provinces: Beijing, Sichuan, etc.) $1,500–$2,300 (historical range) Typically at prior pricing standards
Public IMD channel Public base + 30–60% service premium Includes English service, expedited reporting
Private international hospital / third-party premium imaging center Comparable to or slightly below public Shanghai Quanjing, US-China Joint, etc.

Compared with PET-CT: post-adjustment ratio is 1.3–1.4× (historically commonly 2×, now narrowed).

Compared with US: US PET-MR typically costs $3,500–$5,000+ USD; Chinese public hospitals run approximately 30–40% of US pricing.

Examination Workflow

PET-MR workflow is somewhat longer than PET-CT:

Preparation (similar to PET-CT):

  • 6 hours fasting
  • Blood glucose control
  • Avoid vigorous exercise for 24 hours
  • MR safety screening: check for metallic implants (pacemakers, prosthetic joints, aneurysm clips, etc.) — this is a hard requirement for MR examinations

Typical examination day timeline:

Time Activity
8:00 arrival Blood glucose check + MR safety screening
8:15 Inject 18F-FDG (or PSMA, FAPI, DOTATATE)
8:30–9:30 Rest quietly for 60 minutes
9:30 Enter PET-MR scanning room
9:30–11:00 Scan — 45–90 minutes (longer than PET-CT due to MR sequence time)
11:00 Examination complete
Total on-site time approximately 3–4 hours

Report delivery:

  • Standard outpatient: 2–3 business days
  • IMD channel: can be expedited to next-day (Chinese-English bilingual)

How to Decide Between PET-MR and PET-CT?

Prefer PET-MR when:

  • Brain tumors, neurodegenerative diseases, epilepsy
  • Pediatric or young patients (radiation sensitivity)
  • Hepatobiliary and pancreatic cancers
  • Prostate cancer (especially local staging, combined with PSMA)
  • Head and neck cancers
  • Gynecological cancers (pelvic staging)
  • Cardiac sarcoidosis, myocarditis, viability assessment
  • Multiple myeloma and bone marrow disease

Prefer PET-CT when:

  • Whole-body cancer staging (especially lung, breast, lymphoma where systemic evaluation is primary)
  • Need to complete imaging quickly (PET-CT is ~30 minutes shorter than PET-MR)
  • Contraindicated metallic implants for MR
  • Cost is the priority (PET-CT is less expensive)

Both may be appropriate when:

  • Initial comprehensive staging of complex or rare cancers
  • High-net-worth patients prioritizing complete evaluation
  • Academic research or clinical trial enrollment

Practical principle: for the majority of international patients, PET-CT is sufficient. PET-MR is “a precision tool for specific indications,” not “a comprehensive upgrade to PET-CT.”

Common Questions

Can I travel to China specifically for PET-MR? Yes. Beijing, Shanghai, Guangzhou, Hangzhou, and Chengdu all have PET-MR centers. If your condition falls into one of the eight PET-MR-preferred scenarios (neurological, pediatric, hepatobiliary, prostate, head and neck, gynecological, cardiac, bone marrow disease), choosing a PET-MR center is worth the consideration.

How does the quality of Chinese PET-MR reports compare to Western centers? Chinese major Tier-3A nuclear medicine and radiology joint reading of PET-MR matches Western top centers. Xuanwu Hospital, West China, Fudan Zhongshan, and others participate in international multicenter studies.

Can PSMA PET-MR be done? Yes — primarily at strong nuclear medicine centers in Beijing, Shanghai, and Guangzhou. Tracer availability needs to be confirmed with the hospital in advance (68Ga-PSMA has a short half-life, requiring an on-site or nearby cyclotron).

Is PET-MR safe? Are there contraindications? PET-MR’s radiation dose is meaningfully lower than PET-CT. MR contraindications: older pacemakers, aneurysm clips, implantable insulin pumps, cochlear implants, etc. — these must be disclosed to the physician in advance. Modern MR-compatible pacemakers and implants may be eligible but require specialized evaluation.

How long is the wait for PET-MR in China? Top centers may require 1–3 weeks advance scheduling — total PET-MR units remain limited and demand is high. Through the IMD channel or a coordination service, this can typically be expedited to 3–7 days.

As an international patient, can I confirm a PET-MR slot before traveling to China? Yes. MedCareInChina can confirm your PET-MR slot before you travel — avoiding the surprise of a 2-week wait upon arrival.

Bottom Line

PET-MR availability in China:

  • 50+ units installed nationwide (2024 survey), growing rapidly
  • Concentrated in Beijing, Shanghai, Guangzhou, Hangzhou, Chengdu
  • The 2023 regulatory downgrade (Class A → Class B) has accelerated installations

Best-suited scenarios: neurological, pediatric oncology, hepatobiliary/pancreatic, prostate, head and neck, gynecological, cardiac, multiple myeloma/bone marrow — these eight categories meaningfully outperform PET-CT.

Not suited: most whole-body cancer screening — PET-CT remains sufficient.

Pricing: typically 1.3–1.4× PET-CT, in the range of $1,290–$2,300 USD (depending on hospital and province).

If you’re unsure whether PET-CT or PET-MR is more appropriate for your case, send us a brief case description. MedCareInChina will recommend based on your specific case and the optimal center’s accessibility.

Start with a free Pathway Scan. We will tell you whether China is worth further consideration and which type of next step may fit. The free scan does not include hospital or doctor recommendations, medical advice, individualized cost estimates, insurance determinations, or treatment planning.

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. Chinese Medical Association Nuclear Medicine Branch 2024 National Survey — 51 PET-MR units installed in mainland China (23 four years earlier). https://chinanm.cma.org.cn/attach/0/3be93211e1354cb78836b21cec400fb6.pdf
  2. “14th Five-Year Plan” Large Medical Equipment Configuration Plan — Total PET-MR target 210 units, 141 new installations. Shanghai 21, Beijing 16, Guangdong 16. Source: GSCWZFW (2023) No. 18 https://nirp.chinacdc.cn/fsaqssjb/fswsfgbzsjb/fgsjb/gfxwjsjb/202502/W020250428534267263625.pdf
  3. PET-MR Regulatory Downgrade 2023 — National Health Commission’s “2023 Large Medical Equipment Configuration License Management Catalog” reclassified PET-MR from Class A to Class B. https://www.gov.cn/zhengce/zhengceku/2023-03/21/content_5747678.htm
  4. Xuanwu Hospital CAMIND Multi-Tracer PET-MR Clinical Trial — NCT06092125, 2022–2028. https://clinicaltrials.gov/study/NCT06092125
  5. Pediatric PET-MR Radiation Dose Reduction — Radiation dose ~3–5 mSv, approximately 70% reduction compared with PET-CT. Source: DXY https://y.dxy.cn/hospital/6198/qjyx/article/731641/
  6. PET-MR Advantages for Hepatobiliary/Pancreatic Cancers — Comparison of total-body PET and PET-MR for liver metastasis diagnosis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116365/
  7. PSMA PET-MR Prostate Cancer Staging — 68Ga-PSMA PET-MR superior to PET-CT for prostate local staging. https://www.hanspub.org/journal/paperinformation?paperid=81883
  8. PET-MR Applications in Head and Neck Cancer — PET-MR superior to PET-CT for oropharyngeal squamous cell carcinoma local-regional staging. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160406/
  9. Provincial PET-MR Price Adjustments 2025 — Shanghai full-body ≤US$1,350, Guangdong ≈US$1,290–1,310. Sources: Sina Finance https://finance.sina.com.cn/jjxw/2025-05-16/doc-inewttpc4438743.shtml ; CLS https://www.cls.cn/detail/2037815